Skip to content

Standard shipping $60 · Express shipping $80

KestrelPeptides

Quality & TestingSeptember 1, 2026 · 5 min read

How research peptides are made: synthesis, purification and lyophilization

From solid-phase synthesis to preparative HPLC and freeze-drying: how a peptide sequence becomes a sealed vial of research material, and what each step means for quality.

By Kestrel Peptides team

Quality & Testing

Every research peptide begins as a sequence written on paper. Turning that sequence into a sealed vial of dry, well-characterized material takes four broad stages: assembling the chain, releasing it from its support, purifying it, and freeze-drying it. Knowing how each stage works makes a certificate of analysis far easier to read.

Solid-phase peptide synthesis

Almost all research peptides are made by solid-phase peptide synthesis (SPPS), a method introduced in the 1960s that remains the standard approach today. The growing chain is anchored by its C-terminus to an insoluble resin bead and built one amino acid at a time toward the N-terminus. Because the chain stays attached to the support, excess reagents and by-products are simply washed away after every step, avoiding the laborious intermediate purifications of older solution-phase methods.

The synthesis cycle

Each amino acid is added through a repeating cycle:

  1. Deprotection. The temporary protecting group on the N-terminus of the growing chain is removed. In the widely used Fmoc strategy, this is done with a mild base.
  2. Activation and coupling. The next amino acid, with its own N-terminus protected, is chemically activated and forms a peptide bond with the newly exposed amine.
  3. Washing. Unreacted reagents and by-products are rinsed away.

The cycle repeats until the full sequence is assembled. Throughout, reactive side chains, such as the amine of lysine or the carboxylic acids of aspartic and glutamic acid, carry more robust protecting groups that stay in place until the very end. This pairing of temporary and permanent protection, each removed under different conditions, is what allows the chain to grow in a controlled order.

Why length and sequence matter

Each coupling is highly efficient but never perfect, and small losses compound. As an illustration, if every step went 99% to completion, a 40-residue chain would reach full length only about two-thirds of the time. Chains that miss a coupling become deletion sequences, lacking a single residue; chains that stop growing become truncated sequences. Longer peptides are therefore harder to make in high purity, which is why a tetrapeptide such as epithalon and a 43-residue sequence such as thymosin beta-4 present very different synthetic challenges.

Hydrophobic stretches can also aggregate on the resin and hinder coupling, which chemists address with repeated couplings, modified building blocks, or adjusted conditions.

SPPS also accommodates building blocks that nature does not use. D-amino acids, non-proteinogenic residues, N-terminal acetyl groups, and C-terminal amides can all be introduced during assembly. Ipamorelin, for example, contains aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and ends in a C-terminal amide that results from the choice of resin.

Cleavage and deprotection

Once the chain is complete, it is released from the resin and stripped of its permanent protecting groups, in Fmoc chemistry typically in a single step using a strong acid, trifluoroacetic acid (TFA). This step generates reactive fragments from the protecting groups, which can attach to sensitive residues such as tryptophan, methionine, cysteine, and tyrosine. To prevent this, the cleavage mixture includes scavengers, compounds that trap those fragments before they can do harm.

The released peptide is then precipitated, commonly in cold ether, collected, and dried. The result is the crude peptide: the target sequence mixed with deletion and truncated sequences, incompletely deprotected chains, and the products of side reactions. For some sequences, further chemistry follows at this stage, such as forming disulfide bonds between cysteine residues.

Purification by preparative HPLC

Crude peptide is purified by reversed-phase high-performance liquid chromatography, the same technique used to measure purity on a certificate of analysis, but at a much larger scale. The crude material is loaded onto a column packed with a hydrophobic stationary phase and eluted with a gradient of water and acetonitrile, usually containing a small amount of TFA. Components separate according to their hydrophobicity and leave the column at different times.

The eluate is collected as a series of fractions across the main peak, and each fraction is checked by analytical HPLC and often by mass spectrometry. Fractions that meet the purity specification are pooled; fractions from the edges of the peak, where closely related impurities overlap with the target, are set aside or purified again. This is a genuine trade-off: stricter fraction selection raises purity but lowers yield. Impurities that differ from the target by a single residue can elute very close to it, which is why high purity demands careful method development and, occasionally, a second purification under different conditions.

Counter-ions and salt exchange

Because TFA is present during both cleavage and purification, purified peptides are typically obtained as TFA salts, with trifluoroacetate ions paired to positively charged groups such as the N-terminus and the side chains of lysine, arginine, and histidine. When a different salt form is preferred, often because residual TFA can interfere with some cell-based assays, the peptide can be exchanged into an acetate or hydrochloride salt by ion-exchange methods or by further chromatography with a different mobile phase.

Counter-ions are part of the finished material. They contribute to its mass, which is one reason a peptide's net peptide content is below 100% even when its purity is high.

Lyophilization

The pooled, purified solution is then freeze-dried, a process called lyophilization. It proceeds in three stages:

  1. Freezing. The solution is frozen completely.
  2. Primary drying. Under deep vacuum, the ice sublimes directly from solid to vapor, while the temperature is controlled so that the frozen structure does not collapse.
  3. Secondary drying. The temperature is raised gradually to remove water that remains bound to the solid.

The product is a porous cake or powder with very low residual moisture. In vial-based formats, a measured volume of solution is often dispensed into each vial before drying, and the vials are stoppered at the end of the cycle, sometimes under vacuum or dry nitrogen. Depending on the sequence, fill amount, and drying conditions, the dried material may appear as a solid cake, a loose powder, or a thin film; this variation is normal.

Why lyophilized powder is stable

Most of the chemical reactions that degrade peptides, including hydrolysis, deamidation, and many oxidation pathways, require water or proceed far faster in solution. Removing water sharply reduces molecular mobility, so these reactions slow dramatically in the dry state. Low storage temperatures slow them further, and a sealed vial keeps out the moisture and oxygen that would otherwise accelerate them.

The dry state has one vulnerability: lyophilized peptides are hygroscopic and readily reabsorb water from the air. That is why vials should be kept sealed, cold, and dry, and allowed to reach room temperature before opening so that condensation does not form inside.

From process to paperwork

Each stage of manufacture leaves a trace on the certificate of analysis. Synthesis and cleavage determine the related impurities that HPLC purity measures. Mass spectrometry confirms that the intended sequence was built. Counter-ions and residual water explain the gap between purity and peptide content. A lot number ties all of these results to a single production run, which is why every COA is specific to one batch.

Every product we sell is lyophilized, sealed, and batch-tested for identity and purity by HPLC and mass spectrometry. All products are supplied for in-vitro laboratory research only and are not for human or veterinary use.

This article is for educational and laboratory-research purposes only. Nothing here is medical advice, and no product sold by Kestrel Peptides is intended for human or veterinary use.

Compounds mentioned

Epithalon vial

Cellular & Mitochondrial

Epithalon

Synthetic pineal tetrapeptide (AEDG)

From$46.00

10 mg · 50 mg

per box (10 vials) · 20 box

Ipamorelin vial

GH Secretagogues

Ipamorelin

Selective ghrelin-receptor agonist

From$32.00

2 mg · 5 mg · 10 mg

per box (10 vials) · 20 box

TB-500 vial

Regenerative Research

TB-500

Thymosin Beta-4

From$46.00

2 mg · 5 mg · 10 mg

per box (10 vials) · 20 box